Immune checkpoint inhibitors targeting PD-1 such as nivolumab or pembrolizumab have proven to be efficacious in treating relapsed and/or refractory cHL25–28, and have also been shown to be effective in PMBCL, PCNSL, and PTL29,30. This evidence concerns the gene PDCD1 and primary central nervous system lymphoma.